Genome-wide DNA methylation analysis reveals epigenetic dysregulation of MicroRNA-34A in TP53-associated cancer susceptibility

Journal of Clinical Oncology

Volumn 34, Issue 30, 2016, Pages 3697-3704

  Samuel, Nardin ^a,b,c   Wilson, Gavin ^a,c   Lemire, Mathieu ^c   Said, Badr Id ^b   Lou, Youliang ^b   Li, Weili ^b   Merino, Diana ^e   Novokmet, Ana ^b   Tran, James ^a,b   Nichols, Kim E ^f   Finlay, Jonathan L ^g   Choufani, Sanaa ^b   Remke, Marc ^b   Ramaswamy, Vijay ^b   Cavalli, Florence M G ^b   Elser, Christine ^d   Meister, Lynn ^h   Taylor, Michael D ^b   Tabori, Uri ^b   Irwin, Meredith ^a,b   Weksberg, Rosanna ^a,b   Wasserman, Jonathan D ^b   Paterson, Andrew D ^b   Hansford, Jordan R ⁱ   Achatz, Maria Isabel W ^j   Hudson, Thomas J ^a,c   Malkin, David ^a,b   more..

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^g NATIONWIDE CHILDREN S HOSPITAL   (United States)

^h JOE DIMAGGIO CHILDREN S HOSPITAL   (United States)

ⁱ ROYAL CHILDREN'S HOSPITAL   (Australia)

^j A C CAMARGO CANCER CENTER   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 34A; PROTEIN P53;

ADOLESCENT; ADRENAL CORTEX CARCINOMA; ADULT; ARTICLE; BRAIN TUMOR; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; FRAMESHIFT MUTATION; GENE DELETION; GENE STRUCTURE; GENOME-WIDE ASSOCIATION STUDY; GERMLINE MUTATION; HUMAN; INFANT; LEUKOCYTE; LOSS OF FUNCTION MUTATION; MALE; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PYROSEQUENCING;

EID: 84992323000     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.6940     Document Type: Article

References (22)

1. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 408:307-310, 2000
2. Gonzalez KD, Noltner KA, Buzin CH, et al: Beyond Li Fraumeni syndrome: Clinical characteristics of families with p53 germline mutations. J Clin Oncol 27:1250-1256, 2009
3. Chen YA, Lemire M, Choufani S, et al: Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium Human Methylation450 microarray. Epigenetics 8:203-209, 2013
4. Tost J, Gut IG: DNA methylation analysis by pyrosequencing. Nat Protoc 2:2265-2275, 2007
5. International Agency for Research on Cancer. IARC TP53 Database. Geneva, Switzerland, World Health Organization, 2015
6. Achatz MI, Olivier M, Le Calvez F, et al: The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett 245:96-102, 2007
7. Cipriano R, Miskimen KL, Bryson BL, et al: Conserved oncogenic behavior of the FAM83 family regulates MAPK signaling in human cancer. Mol Cancer Res 12:1156-1165, 2014
8. Lee SY, Meier R, Furuta S, et al: FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. J Clin Invest 122:3211-3220, 2012
9. Botcheva K, McCorkle SR, McCombie WR, et al: Distinct p53 genomic binding patterns in normal and cancer-derived human cells. Cell Cycle 10:4237-4249, 2011
10. Wei CL, Wu Q, Vega VB, et al: A global map of p53 transcription-factor binding sites in the human genome. Cell 124:207-219, 2006
11. Chung JH, Larsen AR, Chen E, et al: A PTCH1 homolog transcriptionally activated by p53 suppresses Hedgehog signaling. J Biol Chem 289:33020-33031, 2014
12. Lemire M, Zaidi SH, Ban M, et al: Long-range epigenetic regulation is conferred by genetic variation located at thousands of independent loci. Nat Commun 6:6326, 2015
13. National Cancer Institute, National Human Genome Research Institute: The Cancer Genome Atlas.
14. Raver-Shapira N, Marciano E, Meiri E, et al: Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26:731-743, 2007
15. Chang TC, Wentzel EA, Kent OA, et al: Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26:745-752, 2007
16. He L, He X, Lim LP, et al: A microRNA component of the p53 tumour suppressor network. Nature 447:1130-1134, 2007
17. Lodygin D, Tarasov V, Epanchintsev A, et al: Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7:2591-2600, 2008
18. Bader AG: miR-34 - A microRNA replacement therapy is headed to the clinic. Front Genet 3:120, 2012
19. Hermeking H: MicroRNAs in the p53 network: Micromanagement of tumour suppression. Nat Rev Cancer 12:613-626, 2012
20. Merino DM, Shlien A, Villani A, et al: Molecular characterization of choroid plexus tumors reveals novel clinically relevant subgroups. Clin Cancer Res 21:184-192, 2015
21. Trang P, Wiggins JF, Daige CL, et al: Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther 19:1116-1122, 2011
22. Di Martino MT, Leone E, Amodio N, et al: Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: In vitro and in vivo evidence. Clin Cancer Res 18:6260-6270, 2012